Sharawi, Z.W.; Abass, S.A.; Zubair, M.A.; Hegazy, R.A.; Farrag, F.A.; Hamdi, A.; El-Magd, M.A.; Elgazar, A.A.
Khellin Mitigates Cisplatin-Induced Renal Injury by Targeting Oxidative Stress, Inflammation, and Apoptosis: Integration of Network Pharmacology, Molecular Docking, and Preclinical Validation. Pharmaceuticals 2025, 18, 836.
https://doi.org/10.3390/ph18060836
AMA Style
Sharawi ZW, Abass SA, Zubair MA, Hegazy RA, Farrag FA, Hamdi A, El-Magd MA, Elgazar AA.
Khellin Mitigates Cisplatin-Induced Renal Injury by Targeting Oxidative Stress, Inflammation, and Apoptosis: Integration of Network Pharmacology, Molecular Docking, and Preclinical Validation. Pharmaceuticals. 2025; 18(6):836.
https://doi.org/10.3390/ph18060836
Chicago/Turabian Style
Sharawi, Zeina W., Shimaa A. Abass, Manal A. Zubair, Rabab A. Hegazy, Foad A. Farrag, Abdelrahman Hamdi, Mohammed A. El-Magd, and Abdullah A. Elgazar.
2025. "Khellin Mitigates Cisplatin-Induced Renal Injury by Targeting Oxidative Stress, Inflammation, and Apoptosis: Integration of Network Pharmacology, Molecular Docking, and Preclinical Validation" Pharmaceuticals 18, no. 6: 836.
https://doi.org/10.3390/ph18060836
APA Style
Sharawi, Z. W., Abass, S. A., Zubair, M. A., Hegazy, R. A., Farrag, F. A., Hamdi, A., El-Magd, M. A., & Elgazar, A. A.
(2025). Khellin Mitigates Cisplatin-Induced Renal Injury by Targeting Oxidative Stress, Inflammation, and Apoptosis: Integration of Network Pharmacology, Molecular Docking, and Preclinical Validation. Pharmaceuticals, 18(6), 836.
https://doi.org/10.3390/ph18060836
